OpenAI has acquired Orchestra Bio, a startup focused on AI agents for pharmaceutical drug development. This acquisition highlights the growing trend of AI companies entering the life sciences sector. OpenAI plans to integrate Orchestra's technology and team into its Rosalind platform for life sciences researchers. Orchestra's AI agents are designed to automate tasks like study monitoring and timeline tracking in drug development. Both OpenAI and its rival Anthropic are aiming for AI agents to connect scientific discoveries with actionable steps for advancing treatments. Financial details of the OpenAI acquisition were not disclosed. AI companies are increasingly seeking to apply their technology to solve major global challenges and transform industries. This ambition is driving acquisitions, as seen with Anthropic's purchase of Coefficient Bio. OpenAI's specialized GPT-Rosalind model, introduced in April, is already assisting researchers in complex scientific problems. The company also has existing partnerships with major pharmaceutical firms to integrate AI into their R&D processes. OpenAI aims to significantly shorten the lengthy timeline for developing new medicines. Meanwhile, Anthropic is also making substantial strides in life sciences with its Claude Science platform and its own biological research lab. The broader trend indicates that the AI race is moving beyond model development towards practical industry applications.